Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association
Sharon Cresci(Washington University in St. Louis), Matthew J. Wolf(Mayo Clinic), David E. Lanfear(Henry Ford Health System), Anjali Owens(University of Pennsylvania), Carolyn M. Reilly, Ferhaan Ahmad(University of Iowa), Lisa de las Fuentes(Washington University in St. Louis), Mirnela Byku, Naveen L. Pereira(Mayo Clinic)
Cited by 60
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity
|Cell Metabolism|2016|866
Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy
|Journal of the American College of Cardiology|2002|518